European Network linking informatics and genomics of helper T cells

Acronym

ENLIGHT-TEN

Description of the granted funding

ENLIGHT-TEN is a European Network Linking Informatics and Genomics of Helper T cells: our mission is to provide cross-disciplinary training in cellular immunology and big data analysis such that we train a new generation of researchers to fully exploit the power of emerging technological platforms. Our network of TEN beneficiaries combines T cell expertise with state-of-the-art technologies such as next generation sequencing (NGS), bioinformatics, multi-colour flow cytometry, preclinical models and tailored genome editing. Trainees will acquire a comprehensive knowledge in T cell immunology and the capacity to generate and interrogate big data sets as well as expertise in identifying novel biomarkers and developing therapeutic concepts. As such the training programme will provide an ideal stepping-stone for creative and innovative early stage researchers (ESRs) to enter and strengthen Europe’s academia as well as pharmaceutical and bioinformatics companies. The research focus of the network lies in the identification of extrinsic and intrinsic factors that control development, differentiation and plasticity of helper T cell subsets with particular emphasis on how T cell differentiation impacts on human diseases. The generation of large data sets is an emerging and challenging field, and there is high demand in both the academic sector as well as pharmaceutical companies for researchers to be able to analyse, integrate and exploit this rich source of information. ENLIGHT-TEN will combine the individual strengths of innovative laboratories and enterprises from complementary disciplines to provide unique interdisciplinary training for 13 ESRs, placing them at the forefront of this emerging field. Trainees will be empowered to perform cutting-edge analysis of the steadily increasing number of different T cell subsets, which play highly diverse and critical roles in the development of autoimmune diseases, making them a key target for pharmaceutical companies.
Show more

Starting year

2015

End year

2019

Granted funding

269 145.36 €
Participant
UNIVERSITY COLLEGE LONDON (UK)
273 287.88 €
Participant
BAYER AKTIENGESELLSCHAFT (DE)
145 376.28 €
Participant
Abcam plc (UK)
Participant
CRISPR Therapeutics Limited (UK)
Participant
AFFIRIS AG (AT)
Participant
NOVIMMUNE SA (CH)
Participant
QIAGEN AARHUS AS (DK)
249 216.48 €
Participant
EAGLE GENOMICS LIMITED (UK)
Participant
Genomatix Software GmbH (DE)
Participant
HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH (DE)
498 432.96 €
Coordinator
THE BABRAHAM INSTITUTE (UK)
546 575.76 €
Participant
INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES (PT)
476 712.72 €
Participant
THE WELLCOME TRUST LIMITED (UK)
273 287.88 €
Participant
MEDIZINISCHE UNIVERSITAET WIEN (AT)
255 934.08 €
Participant
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR)
262 875.6 €
Participant

Amount granted

3 354 685 €

Funder

European Union

Funding instrument

Marie Skłodowska-Curie Innovative Training Networks (ITN)

Framework programme

Horizon 2020 Framework Programme

Call

Programme part
EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions (5220)
Fostering new skills by means of excellent initial training of researchers (5221)
Topic
Marie Skłodowska-Curie Innovative Training Networks (ITN-ETN) (MSCA-ITN-2015-ETN)
Call ID
H2020-MSCA-ITN-2015

Other information

Funding decision number

675395

Identified topics

genes, genetics